A carregar...
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis
GIFT‐I is a phase 3 trial evaluating the efficacy and safety of a 12‐week regimen of coformulated ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) for treatment of Japanese hepatitis C virus genotype 1b–infected patients. It consists of a double‐blind, placebo‐controlled substudy of patients withou...
Na minha lista:
Publicado no: | Hepatology |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
John Wiley and Sons Inc.
2015
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5049673/ https://ncbi.nlm.nih.gov/pubmed/26147154 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.27972 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|